Figure 5From: Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines The inhibitory effect of gemcitabine and docetaxel at different concentrations combined with dasatinib IC 25 and the coefficient of drug interaction (CDI). CDI < 1 indicates synergism, CDI < 0.7 significant synergism, CDI = 1 additivity and CD > 1 antagonism. In SK-UT-1, the combination of gemcitabine-dasatinib, at all concentrations analyzed demonstrated decreased cell viability (A) and yielded a CDI <1 indicating synergistic effects (average CDI = 0.72) (B); the combination of docetaxel-dasatinib demonstrated decreased cell viability (C) and synergistic effects (average CDI = 0.80) (D). In SK-UT-1B the combination of gemcitabine-dasatinib, at all concentrations analyzed demonstrated decreased cell viability (E) and yielded a CDI <1 indicating synergistic effects (average CDI = 0.83) (F); the combination of docetaxel-dasatinib demonstrated decreased cell viability (G) and synergistic effects (CDI = 0.93) (H).Back to article page